S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.71 CNY -1.74%
Market Cap: 35.4B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note

Shenzhen Salubris Pharmaceuticals Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Salubris Pharmaceuticals Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Pre-Tax Income
ÂĄ666.1m
CAGR 3-Years
45%
CAGR 5-Years
-11%
CAGR 10-Years
-5%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
-ÂĄ769m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View

Market Cap
34.6B CNY
Industry
Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. stands as a dynamic player in the pharmaceutical landscape, tracing its origins to China’s bustling hub of innovation, Shenzhen. From its inception, Salubris has steadily cultivated a robust portfolio, deeply rooted in the development, production, and commercialization of a wide array of pharmaceutical products. With a steadfast focus on cardiovascular and cerebrovascular medications, the company has adeptly positioned itself to meet significant medical needs, leveraging its expertise to produce both traditional and novel therapies. This focus is complemented by an ambitious expansion into biopharmaceuticals, a sector that holds significant potential for growth. Salubris thrives by combining its innovative R&D capabilities with efficient production processes, ensuring that its offerings not only reach a broad customer base but also adhere to stringent quality standards. The company’s business model revolves around a meticulously crafted combination of research innovation and strategic partnerships. By investing significantly in research and development, Salubris ensures a pipeline filled with promising drugs poised to address prevalent health issues. The company maximizes its revenues through its sales network, which extends beyond domestic borders, tapping into international markets where demand for high-quality pharmaceuticals continues to rise. Additionally, Salubris has been proactive in pursuing collaborations and partnerships, both to bolster its research capabilities and to navigate regulatory landscapes more effectively. By marrying these strategic approaches, Salubris not only sustains its competitive edge but also ensures a steady growth trajectory, embodying a business narrative that resonates with resilience and forward-thinking ambition.

Intrinsic Value
25.4 CNY
Overvaluation 20%
Intrinsic Value
Price
S

See Also

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Pre-Tax Income?
Pre-Tax Income
666.1m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Pre-Tax Income amounts to 666.1m CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-5%

Over the last year, the Pre-Tax Income growth was 2%. The average annual Pre-Tax Income growth rates for Shenzhen Salubris Pharmaceuticals Co Ltd have been 45% over the past three years , -11% over the past five years , and -5% over the past ten years .

Back to Top